Novartis' Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial

Novartis AG (NYSE: NVS) reported data from the Phase 3 CANOPY-2 study evaluating canakinumab (ACZ885) in advanced or metastatic non-small cell lung cancer (NSCLC).

The study did not meet the primary endpoint of overall survival (OS).

The trial evaluated canakinumab plus chemotherapy agent docetaxel in adults with NSCLC whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy.

Canakinumab development program continues with two Phase 3 CANOPY trials, evaluating the antibody in first-line and adjuvant settings.

Novartis and CANOPY-2 investigators will analyze the study data and are expected to submit the findings for presentation at an upcoming medical meeting.

Canakinumab is a human monoclonal antibody that could enhance anti-tumor immune response and reduce tumor cell proliferation, survival, and invasiveness.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types